Trial Profile
A Randomized, Open-label, Single Dose, 2-way Crossover Study to Compare the Safety and Pharmacokinetic Characteristics After Administration of HIP1503 and HGP1103 in Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs HIP 1503 (Primary) ; Solifenacin (Primary)
- Indications Overactive bladder
- Focus Pharmacokinetics
- Sponsors Hanmi Pharmaceutical
- 25 Oct 2016 New trial record